Johnson & Johnson (JNJ) Q3 2025 Financial Results Summary

On October 14, 2025, Johnson & Johnson (NYSE: JNJ) announced its financial results for the third quarter of 2025. Below is a summary of the key metrics and developments from the report.

Financial Highlights

• Reported Sales Growth: Increased by 6.8% to $24.0 Billion compared to $22.5 Billion in Q3 2024.
• Operational Sales Growth: Achieved 5.4% growth, with adjusted operational sales growth at 4.4%.
• Net Earnings: Rose by 91.2% to $5.2 Billion, reflecting significant profit compared to $2.7 Billion in Q3 2024.
• Earnings Per Share (EPS):
• Diluted EPS: Increased 91.0% to $2.12 from $1.11 in the same period last year.
• Adjusted EPS: Grew 15.7% to $2.80, compared to $2.42 in Q3 2024.

Key Operational Metrics

• Free Cash Flow: Approximately $14.2 Billion, slight decrease from $14.5 Billion in Q3 2024.
• Full-Year Sales Guidance: Increased 2025 estimated reported sales to $93.7 Billion, representing a midpoint growth of 5.7%; reaffirmed full-year adjusted EPS guidance of $10.85.

Regional Sales Performance

• U.S. Sales: Increased by 6.2% to $13.7 Billion from $12.9 Billion in Q3 2024.
• International Sales: Rose 7.6% to $10.3 Billion, compared to $9.6 Billion in the previous year.

Segment Sales Performance

• Innovative Medicine: Reported sales increased 6.8% to $15.6 Billion driven by products in Oncology and Immunology.
• MedTech: Grew 6.8% to $8.4 Billion, led primarily by specialized cardiovascular products and wound closure products.

Recent Innovations and Approvals

• Approved INLEXZO for high-risk non-muscle invasive bladder cancer and TREMFYA in ulcerative colitis, expanding treatment options in oncology.
• Landmark data emerged for RYBREVANT plus LAZCLUZE in improving survival rates for non-small cell lung cancer.
• Significant advancements reported in cardiovascular health through the DanGer Shock study showing long-term survival benefits of the Impella Heart Pump.

Shareholder Actions

• Dividend Declaration: Information on quarterly dividends was not specified in the report. Further information may be available in the investor relations section of the company’s website.
• Share Repurchase: No share repurchase details were provided in this earnings report.

Conclusion

Johnson & Johnson’s Q3 2025 results showcase robust growth across financial metrics, strengthened by successful product innovations and strategic priorities focused on key healthcare sectors. The company anticipates continued positive momentum into the next quarters, supported by a strong operational pipeline and elevated sales outlook.

For more news and updates, stakeholders are encouraged to visit the investor relations section on Johnson & Johnson’s official website.